Laura San-Segundo

5PUBLICATIONS
26CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 11, 2024
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.

Andrea Díaz-Tejedor, Javier Rodríguez-Ubreva, Laura Ciudad

|Mar 20, 2024
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.

Andrea Álvarez-Vázquez, Laura San-Segundo, Pilar Cerveró-García

|Jul 27, 2022
Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity.

María Ovejero-Sánchez, Jorge Rubio-Heras, María Del Carmen Vicente de la Peña

|Apr 03, 2021
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.

Esperanza M Algarín, Dalia Quwaider, Francisco J Campos-Laborie

|Sep 29, 2020
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.

Teresa Paíno, Lorena González-Méndez, Laura San-Segundo

Pageof 1

Frequent Collaborators

3 joint publications

Teresa Paíno

3 joint publications

Mercedes Garayoa

3 joint publications

Enrique M Ocio

2 joint publications

Luis A Corchete